RU2003136730A - Лечение или профилактика отторжения инсулин-продуцирующего клеточного трансплантата - Google Patents
Лечение или профилактика отторжения инсулин-продуцирующего клеточного трансплантата Download PDFInfo
- Publication number
- RU2003136730A RU2003136730A RU2003136730/15A RU2003136730A RU2003136730A RU 2003136730 A RU2003136730 A RU 2003136730A RU 2003136730/15 A RU2003136730/15 A RU 2003136730/15A RU 2003136730 A RU2003136730 A RU 2003136730A RU 2003136730 A RU2003136730 A RU 2003136730A
- Authority
- RU
- Russia
- Prior art keywords
- combination according
- antibody
- insulin
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 230000002265 prevention Effects 0.000 title claims 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract 10
- 239000003795 chemical substances by application Substances 0.000 claims abstract 7
- 230000001506 immunosuppresive effect Effects 0.000 claims abstract 7
- 150000002596 lactones Chemical class 0.000 claims abstract 7
- 150000003839 salts Chemical group 0.000 claims abstract 6
- 102000004877 Insulin Human genes 0.000 claims abstract 5
- 108090001061 Insulin Proteins 0.000 claims abstract 5
- 102000010789 Interleukin-2 Receptors Human genes 0.000 claims abstract 5
- 108010038453 Interleukin-2 Receptors Proteins 0.000 claims abstract 5
- 210000004027 cell Anatomy 0.000 claims abstract 5
- 150000001875 compounds Chemical class 0.000 claims abstract 5
- 229940125396 insulin Drugs 0.000 claims abstract 5
- 229940124073 Complement inhibitor Drugs 0.000 claims abstract 4
- 239000004074 complement inhibitor Substances 0.000 claims abstract 4
- 210000004698 lymphocyte Anatomy 0.000 claims abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 4
- 230000000295 complement effect Effects 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical group C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical group C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- KKGQTZUTZRNORY-UHFFFAOYSA-N fingolimod Chemical group CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1 KKGQTZUTZRNORY-UHFFFAOYSA-N 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29706901P | 2001-06-08 | 2001-06-08 | |
| US60/297,069 | 2001-06-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2003136730A true RU2003136730A (ru) | 2005-05-20 |
Family
ID=23144725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003136730/15A RU2003136730A (ru) | 2001-06-08 | 2002-06-07 | Лечение или профилактика отторжения инсулин-продуцирующего клеточного трансплантата |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US20030003099A1 (https=) |
| EP (1) | EP1429845B1 (https=) |
| JP (1) | JP4476623B2 (https=) |
| CN (1) | CN1524002A (https=) |
| AT (1) | ATE424893T1 (https=) |
| AU (1) | AU2002320828B2 (https=) |
| BR (1) | BR0209319A (https=) |
| CA (1) | CA2445605A1 (https=) |
| DE (1) | DE60231522D1 (https=) |
| ES (1) | ES2322442T3 (https=) |
| IL (1) | IL158384A0 (https=) |
| NO (1) | NO20035434D0 (https=) |
| NZ (1) | NZ529044A (https=) |
| PL (1) | PL364359A1 (https=) |
| PT (1) | PT1429845E (https=) |
| RU (1) | RU2003136730A (https=) |
| WO (1) | WO2002100148A2 (https=) |
| ZA (1) | ZA200307893B (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2433117C2 (ru) * | 2005-12-15 | 2011-11-10 | Мицубиси Танабе Фарма Корпорейшн | Аминное соединение и его применение в медицинских целях |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2267993T3 (es) * | 2001-02-22 | 2007-03-16 | Novartis Ag | Uso de agentes de migracion acelerada de linfocitos para la fabricacion de un medicamento para el tratamiento de la funcion retardada del injerto. |
| ES2528362T3 (es) * | 2004-05-14 | 2015-02-09 | Alexion Pharmaceuticals, Inc. | Prolongación de la supervivencia de un aloinjerto por inhibición de la actividad del complemento |
| CN101014329B (zh) * | 2004-07-16 | 2010-09-08 | 杏林制药株式会社 | 用于对器官或组织的移植的排异反应或骨髓移植的移植物抗宿主反应预防或治疗的药物组合物 |
| KR20140095109A (ko) * | 2004-11-29 | 2014-07-31 | 노파르티스 아게 | Ｓ１ｐ 수용체 효능제의 투여 용법 |
| US20080206240A1 (en) * | 2005-02-08 | 2008-08-28 | Shreeram Aradhye | Antilymphocyte Antibody Induction |
| US20090191218A1 (en) | 2005-05-11 | 2009-07-30 | Fengchun Li | DNA Vaccines And Methods For The Prevention Of Transplantation Rejection |
| DE602006015373D1 (de) * | 2005-05-11 | 2010-08-19 | Univ Loma Linda | Zusammensetzungen und Verfahren zur Prävention und Behandlung von immunvermittelten Entzündungskrankheiten |
| RS53864B1 (sr) * | 2006-03-02 | 2015-08-31 | Alexion Pharmaceuticals, Inc. | Produžavanje preživljavanja alografta inhibiranjem aktivnosti komplementa |
| EP2069375B1 (en) * | 2006-09-28 | 2012-03-28 | Loma Linda University | Apoptotic cell-mediated transfection of mammalian cells with interfering RNA |
| WO2009099174A1 (ja) | 2008-02-07 | 2009-08-13 | Kyorin Pharmaceutical Co., Ltd. | アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤 |
| EP3332801B1 (en) * | 2008-03-12 | 2023-09-13 | Loma Linda University | Dna vaccines and methods for the prevention of transplantation rejection |
| HUE033168T2 (en) | 2008-03-17 | 2017-11-28 | Actelion Pharmaceuticals Ltd | Dosage regimen for selective SIP1 receptor agonist |
| CA2743232C (en) * | 2008-11-11 | 2015-12-29 | Novartis Ag | Crystalline forms of fingolimod hcl |
| MX2011004924A (es) * | 2008-11-11 | 2011-05-30 | Novartis Ag | Sales de fingolimod. |
| EP2455876A3 (en) * | 2009-06-30 | 2013-01-30 | Lifescan Scotland Limited | System and method for diabetes management |
| JP5654587B2 (ja) * | 2009-06-30 | 2015-01-14 | ライフスキャン・インコーポレイテッドＬｉｆｅｓｃａｎ，Ｉｎｃ． | 基礎インスリン療法を算出する分析物試験方法及び装置 |
| ES2631610T3 (es) * | 2009-09-29 | 2017-09-01 | Lifescan Scotland Limited | Dispositivo y método de ensayo de analito para la gestión de la diabetes |
| WO2011106029A1 (en) * | 2010-02-25 | 2011-09-01 | Lifescan Scotland Limited | Analyte testing method and system with high and low blood glucose trends notification |
| US11680273B2 (en) | 2011-09-23 | 2023-06-20 | Loma Linda University | Treatment of autoimmune diseases |
| US10813987B2 (en) | 2011-09-23 | 2020-10-27 | Loma Linda University | Method for inducing a tolerogenic immune response |
| CN114306643A (zh) * | 2021-11-30 | 2022-04-12 | 中国科学院昆明动物研究所 | 一种恒河猴免疫抑制模型的构建方法及在car-t细胞植活上的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5604229A (en) * | 1992-10-21 | 1997-02-18 | Yoshitomi Pharmaceutical Industries, Ltd. | 2-amino-1,3-propanediol compound and immunosuppressant |
| US5679546A (en) * | 1993-09-24 | 1997-10-21 | Cytomed, Inc. | Chimeric proteins which block complement activation |
| WO1995023512A1 (en) * | 1994-03-03 | 1995-09-08 | Alexion Pharmaceuticals, Inc. | Terminal complement inhibitor fusion genes and proteins |
| GB9624038D0 (en) * | 1996-11-19 | 1997-01-08 | Sandoz Ltd | Organic compounds |
| JPH1180026A (ja) * | 1997-09-02 | 1999-03-23 | Yoshitomi Pharmaceut Ind Ltd | 新規免疫抑制剤、その使用方法およびその同定方法 |
| ES2267993T3 (es) * | 2001-02-22 | 2007-03-16 | Novartis Ag | Uso de agentes de migracion acelerada de linfocitos para la fabricacion de un medicamento para el tratamiento de la funcion retardada del injerto. |
-
2002
- 2002-06-07 ES ES02754637T patent/ES2322442T3/es not_active Expired - Lifetime
- 2002-06-07 WO PCT/EP2002/006278 patent/WO2002100148A2/en not_active Ceased
- 2002-06-07 CA CA002445605A patent/CA2445605A1/en not_active Abandoned
- 2002-06-07 IL IL15838402A patent/IL158384A0/xx unknown
- 2002-06-07 PL PL02364359A patent/PL364359A1/xx not_active Application Discontinuation
- 2002-06-07 RU RU2003136730/15A patent/RU2003136730A/ru not_active Application Discontinuation
- 2002-06-07 PT PT02754637T patent/PT1429845E/pt unknown
- 2002-06-07 AT AT02754637T patent/ATE424893T1/de active
- 2002-06-07 AU AU2002320828A patent/AU2002320828B2/en not_active Ceased
- 2002-06-07 CN CNA028098498A patent/CN1524002A/zh active Pending
- 2002-06-07 DE DE60231522T patent/DE60231522D1/de not_active Expired - Lifetime
- 2002-06-07 NZ NZ529044A patent/NZ529044A/en unknown
- 2002-06-07 BR BR0209319-7A patent/BR0209319A/pt not_active IP Right Cessation
- 2002-06-07 US US10/164,755 patent/US20030003099A1/en not_active Abandoned
- 2002-06-07 EP EP02754637A patent/EP1429845B1/en not_active Expired - Lifetime
- 2002-06-07 JP JP2003502981A patent/JP4476623B2/ja not_active Expired - Fee Related
-
2003
- 2003-10-09 ZA ZA200307893A patent/ZA200307893B/en unknown
- 2003-12-05 NO NO20035434A patent/NO20035434D0/no not_active Application Discontinuation
-
2006
- 2006-03-09 US US11/372,383 patent/US20060153842A1/en not_active Abandoned
-
2008
- 2008-04-22 US US12/107,726 patent/US20080199465A1/en not_active Abandoned
-
2011
- 2011-06-06 US US13/154,106 patent/US20110236382A1/en not_active Abandoned
-
2013
- 2013-12-05 US US14/098,179 patent/US20140093502A1/en not_active Abandoned
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2433117C2 (ru) * | 2005-12-15 | 2011-11-10 | Мицубиси Танабе Фарма Корпорейшн | Аминное соединение и его применение в медицинских целях |
| US8809304B2 (en) | 2005-12-15 | 2014-08-19 | Mitsubishi Tanabe Pharma Corporation | Amine compound and use thereof for medical purposes |
Also Published As
| Publication number | Publication date |
|---|---|
| PL364359A1 (en) | 2004-12-13 |
| US20060153842A1 (en) | 2006-07-13 |
| EP1429845A2 (en) | 2004-06-23 |
| NZ529044A (en) | 2008-03-28 |
| JP4476623B2 (ja) | 2010-06-09 |
| CA2445605A1 (en) | 2002-12-19 |
| US20080199465A1 (en) | 2008-08-21 |
| EP1429845B1 (en) | 2009-03-11 |
| DE60231522D1 (de) | 2009-04-23 |
| AU2002320828B2 (en) | 2006-02-02 |
| US20110236382A1 (en) | 2011-09-29 |
| US20140093502A1 (en) | 2014-04-03 |
| WO2002100148A3 (en) | 2004-04-22 |
| US20030003099A1 (en) | 2003-01-02 |
| IL158384A0 (en) | 2004-05-12 |
| WO2002100148A2 (en) | 2002-12-19 |
| ZA200307893B (en) | 2004-09-06 |
| CN1524002A (zh) | 2004-08-25 |
| ATE424893T1 (de) | 2009-03-15 |
| PT1429845E (pt) | 2009-06-15 |
| ES2322442T3 (es) | 2009-06-22 |
| BR0209319A (pt) | 2004-07-20 |
| NO20035434D0 (no) | 2003-12-05 |
| JP2004534788A (ja) | 2004-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2003136730A (ru) | Лечение или профилактика отторжения инсулин-продуцирующего клеточного трансплантата | |
| RU2008119842A (ru) | Производные триазола в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы-1 | |
| RU2487119C2 (ru) | Производные иминопиридина и их применение в качестве микробиоцидов | |
| RU2370495C2 (ru) | Дополнительные гетероциклические соединения и их применение в качестве антагонистов метаботропного глутаматного рецептора | |
| MA58498B1 (fr) | Agonistes hétérocycliques de glp-1 | |
| RU98100481A (ru) | Производные рапамицина | |
| JP2004534788A5 (https=) | ||
| RU2009143333A (ru) | Производные аминодигидротиазина, замещенные циклической группой | |
| DOP2005000076A (es) | "compuestos de aril-o heteroarilamida ortosustituidos" | |
| RU2010115886A (ru) | Cd19-связывающие средства и их применение | |
| MY127082A (en) | Synergistic methods and compositions for treating cancer | |
| RU2009149210A (ru) | Ингибиторы днк-зависимой протеинкиназы (днк-пк) | |
| RU2011106374A (ru) | Циклические ингибиторы 11бета-гидроксистероид-дегидрогеназы 1 | |
| JP2009532453A5 (https=) | ||
| BR0210209A (pt) | Composições contendo zinco para uso antiviral | |
| RU2003111462A (ru) | Замещенные гуанидиды коричной кислоты, способ их получения, их применение в качестве лекарственного средства, а также содержащее их лекарственное средство | |
| MX2020012827A (es) | Compuestos tetrahidro-1h-pirazino[2,1-a]isoindolilquinolina para el tratamiento de enfermedades autoinmunes. | |
| RU2012110380A (ru) | Новое производное 5-фторурацила | |
| RU2013136861A (ru) | Новое производное индола или индазола или его соль | |
| RU2006146215A (ru) | Производные аминопропанола | |
| MX2024012470A (es) | Inhibidores de cinasas dependientes de ciclina 9 (cdk9) | |
| RU2003134629A (ru) | Соединения цефема | |
| RU2009114731A (ru) | Производное пиразолопиримидина | |
| MX2022011242A (es) | Inmunomodulación de o-het/aril azálidos. | |
| RU2003130070A (ru) | Производные бигуанида |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20100413 |